Cytokine analyses demonstrated alterations in circulating inflammatory and remodeling markers; however, predictive modeling indicated that these alone had limited discriminatory performance. Model accuracy improved when variables were integrated with clinical and imaging metrics, suggesting a subset of circulating proteins contributes to disease pathways. Lipidomic profiling revealed distinct remodeling of inflammatory lipid mediator pathways, with clear separation between FA and control driven by coordinated pathway-level changes. Mass spec proteomics and early single-cell immune profiling further identified trends consistent with mitochondrial stress, immune activation, and fibro-inflammatory signaling.
Monday, October 19, 2026
Multi-Omics Biomarker Discovery in Friedreich’s Ataxia Cardiomyopathy
F. Siddiqui, T. Keller, C. Koehring, G. Upadhyay, B. Higgins, T. Zesiewicz, K. Kim, G. Halade, A. Patel, T. Mcdonald. Multi-Omics Biomarker Discovery in Friedreich’s Ataxia Cardiomyopathy [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/multi-omics-biomarker-discovery-in-friedreichs-ataxia-cardiomyopathy/. Accessed October 19, 2026.
Transcriptomic Profiling of Frataxin-Deficient Drosophila melanogaster to Identify Molecular Drivers and Pathway Disruptions in Friedreich’s Ataxia
V. Swarup, R. Yadav, A. Ahuja, P. Yadav, A. Srivastava, D. Garg. Transcriptomic Profiling of Frataxin-Deficient Drosophila melanogaster to Identify Molecular Drivers and Pathway Disruptions in Friedreich’s Ataxia [abstract]. Mov Disord. 2026; 41 (suppl 1). October 19, 2026.
Out of 2035 genes, 1260 were upregulated and 775 downregulated. FBgn0000261 (Catalase) and FBgn0024958 (Irp1A) were significantly down in fh-/- mutants, while FBgn0039561 (mitoferrin) was significantly up.GO enrichment highlighted proteolysis as the top biological process, followed by small molecule metabolism and transmembrane transport. KEGG and REACTOME analyses confirmed enrichment in oxidative phosphorylation, metabolic pathways, and immune processes (FDR<0.001). These defects reveal mitochondrial dysfunction and oxidative stress in the disease model.
Ethical considerations in the conduct of rare disease neuroscience clinical trials
Olugemo, K., Horrigan, J., Busner, J. et al. Ethical considerations in the conduct of rare disease neuroscience clinical trials. Orphanet J Rare Dis (2026). doi:10.1186/s13023-026-04635-5
In this position paper of the International Society of CNS Clinical Trials and Methodology (ISCTM), the Orphan Diseases Working Group examines key ethical considerations specific to rare disease neuroscience clinical trials. We address the challenges of maintaining clinical equipoise in small, often heterogenous populations; the justification and limitations of placebo-controlled designs; the ethical complexities introduced by gene therapies and other biologics, including consent, assent, and participation of vulnerable populations; the imperative for responsible data sharing and transparent communication with patient advocacy organizations; and best practices for compassionate use programs. Drawing on existing regulatory frameworks, published literature, and the collective experience of the working group, we offer recommendations intended to guide sponsors, investigators, regulators, and ethics committees in the ethical design and conduct of these critical trials.
1H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2
sabelle Iltis, Diane Hutter, Khalaf O. Bushara, H. Brent Clark, Myron Gross, Lynn E. Eberly, Christopher M. Gomez, Gülin Öz, 1H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2, Brain Research, Volume 1358, 2010, Pages 200-210, ISSN 0006-8993, doi:10.1016/j.brainres.2010.08.030.
Neuronal loss/dysfunction was indicated in the cerebellar vermis and hemispheres in both diseases by lower total N-acetylaspartate levels than controls. The putative gliosis marker myo-inositol was higher than controls in the vermis and pons in AOA2 and in the vermis in FRDA. Total creatine, another potential gliosis marker, was higher in the cerebellar hemispheres in FRDA relative to controls. Higher glutamine in FRDA and lower glutamate in AOA2 than controls were observed in the vermis, indicating different mechanisms possibly leading to altered glutamatergic neurotransmission. In AOA2, total N-acetylaspartate levels in the cerebellum strongly correlated with the FARS score (p < 0.01).
Edited HSPCs rescue frataxin deficiency and inflammation-driven multisystemic pathology in Friedreich’s ataxia mice
Sivakumar, Anusha & Corl, Alexis & Muñoz, Keneth & Arumugam, Subhashini & Gunes, Betul & Solis, Angelyn & Murthy, Rishika & El-Hachem, Lilas & Pizzo, Donald & Blair, Ian & Rojsajjakul, Teerapat & Mesaros, Clementina & Wan, Xinlong & Rainaldi, Joseph & Badell-Grau, Rafael & Khare, Veenita & Thai, Kevin & Biederman, Kavya & Cherqui, Stephanie. (2026). Edited HSPCs rescue frataxin deficiency and inflammation-driven multisystemic pathology in Friedreich’s ataxia mice. Journal of Clinical Investigation. 136. DOI:10.1172/JCI209546.
Here, we demonstrate that ex vivo CRISPR/Cas9 excision of the GAA expansion in hematopoietic stem and progenitor cells (HSPCs) provides durable, systemic therapy for FRDA. A single infusion of gene-edited Sca1+ HSPCs, mPPL-001, into myeloablative, humanized YG8JR mice resulted in long-term engraftment of donor-derived cells across hematopoietic and FRDA-affected tissues. mPPL-001 increased FXN expression and corrected multiple key pathogenic drivers of FRDA, including mitochondrial stress, microglial and macrophage activation, and inflammatory signaling. These coordinated effects improved motor functions, preserved cerebellar architecture, mitigated cardiac pathology, and promoted survival of insulin-producing β cells in the pancreatic islets of Langerhans.
Glial-specific mitochondrial failure and redox imbalance contribute to regional vulnerability in Friedreich's ataxia
Arabela Sanz-Alcázar, Marta Portillo-Carrasquer, Israel Manjarres-Raza, Maria Pazos-Gil, Fabien Delaspre, Jordi Tamarit, Juan P. Bolaños, Joaquim Ros, Elisa Cabiscol, Glial-specific mitochondrial failure and redox imbalance contribute to regional vulnerability in Friedreich's ataxia, Redox Biology, Volume 98, 2026, 104437, ISSN 2213-2317, doi:10.1016/j.redox.2026.104437.

Highlights: Glial dysfunction, not neuronal failure, is linked to regional degeneration in FA. Satellite glia and sensory neurons show early iron overload and oxidative stress. Astrocytic dysfunction precedes neuronal pathology in the cerebrum and cerebellum. Mitochondrial impairment and iron overload contribute to cell-specific ferroptosis. NRF2-GPX4 axis collapse is associated with disease progression in FA.

Subscribe to:
Posts (Atom)
